Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...

Total net product revenue reached $386 million for 2024, with CEO Tabuteau stating, "Based on the recent performance, Auvelity is on track to reach blockbuster potential." Symbravo received FDA ...

Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $132 and keeps an Outperform rating on the shares. The firm ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...

Auvelity Net Product Sales: $92.6 million for Q4 2024; $291.4 million for full year 2024, representing 89% and 124% year-over-year growth. Sunosi Net Product Revenues: $26.2 million for Q4 2024 ...

AXS-05 is already approved for treating adults with major depressive disorder (MDD) and is being marketed under the brand name Auvelity. Auvelity is the biggest product in Axsome’s portfolio.

Axsome's flagship product, AUVELITY (AXS-05), has been approved for the treatment of major depressive disorder (MDD) and is showing strong commercial performance. The company is now exploring the ...

Axsome Therapeutics' Q4 revenue surged to $118.77 million, surpassing expectations with significant growth in Auvelity sales. Axsome reports progress on multiple drug applications, including ...